Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer-Reference-Cited by-同舟云学术

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer

Published:2019-03 Issue:3 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Almeida Deepak V.¹,Omansen Till F.¹²,Li Si-Yang¹,Lee Jin¹,Grosset Jacques H.¹,Converse Paul J.¹,Nuermberger Eric L.¹

Affiliation:

1. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

2. Infectious Diseases Unit, Department of Internal Medicine, University of Groningen, Groningen, The Netherlands

Abstract

Rifampin (RIF) plus clarithromycin (CLR) for 8 weeks is now the standard of care for Buruli ulcer (BU) treatment, but CLR may not be an ideal companion for rifamycins due to bidirectional drug-drug interactions. The oxazolidinone linezolid (LZD) was previously shown to be active against Mycobacterium ulcerans infection in mice but has dose- and duration-dependent toxicity in humans.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02171-18

Reference28 articles.

1. Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease

2. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

3. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial